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Abstract β-Thalassaemia major is a hereditary haemolytic
anaemia that is treated with multiple blood transfusions. A
major complication of this treatment is iron overload, which
leads to cell death and organ dysfunction. Chelation
therapy, used for iron elimination, requires effective
monitoring of the body burden of iron, for which serum
ferritin levels and liver iron content measured in liver
biopsies are used as markers, but are not reliable. MRI
based on iron-induced T2 relaxation enhancement can be
used for the evaluation of tissue siderosis. Various MR
protocols using signal intensity ratio and mainstream
relaxometry methods have been used, sometimes with
discrepant results. Relaxometry methods using multiple
echoes achieve better sampling of the time domain in which
relaxation mechanisms take place and lead to more precise
results. In several studies the MRI parameters of liver
siderosis have failed to correlate with those of other
affected organs, underlining the necessity for MRI iron
evaluation in individual organs. Most studies have included
children in the evaluated population, but MRI data on very
young children are lacking. Wider application of relaxometry
methods is indicated, with the establishment of universally
accepted MRI protocols, and further studies, including young
children, are needed.
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Introduction
β-Thalassaemia major is a hereditary anaemia characterized
by ineffective erythropoiesis and haemolysis [1]. The under-
lying mechanism is defective production of haemoglobin β-
chains, resulting in excess of α-chains, which are unstable
and precipitate to form intracellular inclusion bodies [2,
3]. This excessive intracellular deposition of α-chain
material is responsible for accelerated apoptosis of the
erythroid precursors and for peripheral haemolysis of the
erythrocytes [3]. By the age of 3 months, severe anaemia
develops leading to increased intestinal iron absorption. To
maintain haemoglobin at a level of 10–12 g/dl, patients
suffering from β-thalassaemia major need to be given
repeated blood transfusions [1]. A major drawback of this
treatment is transfusion siderosis, which, in association with
the increased intestinal iron absorption, apoptosis of the
erythroid precursors and peripheral haemolysis, leads to
iron overload [1].
Iron is ubiquitous in eukaryotic organisms. It is essential
for cellular survival and proliferation and for haemoglobin
synthesis [4, 5]. Human demands for iron are covered
partly by intestinal absorption, but mainly from the
recycling of iron from old or abnormal erythrocytes
phagocytized by macrophages [6]. Iron released from
macrophages binds mainly to transferrin, but also to citrate
and albumin to form non-transferrin-bound iron (NTBI)
which is a toxic form [7–9]. Extracellular iron bound to
transferrin enters the cell via transferrin receptors by a
process of endocytosis. Once iron is released into the
cytoplasm, it enters a poorly defined cellular compartment
termed the labile iron pool (LIP). Iron in this compartment
is loosely bound and therefore is highly toxic [10].
Intracellular iron that is not needed for immediate use is
stored in the form of ferritin which consists of an
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4,500) [5, 11], and is not cytotoxic. When ferritin storage
capacity is exceeded the LIP increases and haemosiderin is
generated from ferritin denaturation [10]. Iron in the form
of haemosiderin is thought to be more cytotoxic [10]. The
iron in the LIP is in both the ferrous (Fe
2+) and ferric (Fe
3+)
forms [12]. Fe
2+ reacts with hydrogen and lipid peroxides
and generates highly toxic hydroxyl and lipid radicals
(Fenton reaction) that damage cellular membranes, proteins
and nucleic acids [4]. Iron overload, just as lack of cellular
iron, may lead to cell death and organ dysfunction.
Iron overload is a major cause of morbidity and
mortality in β-thalassaemia major [1]. Iron accumulates
initially in the reticuloendothelial system (bone marrow,
spleen, liver) and then in the hepatocytes, the heart
(myocytes) and the endocrine glands [1, 9, 13]. In contrast
to the reticuloendothelial cells, the turnover of iron in the
hepatocytes, myocytes and endocrine glands is very low
[9]. Chelation therapy has been used to eliminate excess
iron [1, 7]. Chelatable iron is derived from the catabolism
of haemoglobin in macrophages [14]. Chelators remove
NTBI from the plasma, but they do not interact with ferritin
and haemosiderin at clinically relevant rates [10, 15].
Desferrioxamine (DFO), which is the chelating agent most
widely used over the last 30 years, requires parenteral
administration. It removes mainly extracellular iron and
only a fraction of the intracellular LIP iron [14, 15].
Deferiprone is an oral iron chelator that penetrates the
cellular membrane and chelates intracellular species of
toxic iron [16]. Cellular uptake of chelators takes place at
different rates in different cells [15]. DFO is of low toxicity,
mainly affecting the optic, auditory and skeletal systems
[7]. Skeletal changes develop mainly due to the toxic
effects of DFO on the growth cartilage and are manifested
as disproportionate truncal shortening with loss of seated
height [7]. Adverse effects of deferiprone are arthralgia,
gastrointestinal symptoms, elevated liver enzymes and
rarely agranulocytosis [7, 16].
The effective management of patients, and especially of
children, with thalassaemia requires optimal monitoring of
the toxic effects of both iron overload and excessive
chelation therapy. Serum ferritin has been widely used as
a surrogate marker and a target ferritin level of 1,000 μg/l is
generally recommended [7, 17]. However, serum ferritin
represents only 1% of the total iron pool, and as an acute-
phase protein it is not specific because the levels can be
raised in inflammation (e.g. hepatitis) and liver damage [7,
18, 19]. Chronic liver inflammation is not rare in patients
with thalassaemia, since over 40% of them have positive
anti-hepatitis C virus (HCV) antibodies and more than 50%
have chronic (persistent or active) hepatitis [20, 21]. Liver
iron concentration (LIC) measured on needle biopsy is
currently considered the gold standard for the evaluation of
siderosis [7, 18, 19]. However, needle biopsy is an invasive
technique, it is not easily repeatable and the accuracy of the
resulting LIC measurement is greatly affected by hepatic
inflammation-fibrosis and uneven iron distribution [22].
Furthermore, it appears that cardiac iron overload, which is
the leading cause of death in thalassaemia, cannot be
predicted from the degree of liver siderosis, probably
because of differences in iron kinetics between liver and
heart cells [9]. The use of non-invasive techniques for
monitoring iron overload in each of the affected organs
would be preferable, and to this end MRI has been used
increasingly over the last two decades [19, 22–44]. Other
non-invasive methodologies are too complex, too costly
and not readily available (i.e. magnetic susceptometry), or
lack imaging capability (i.e. magnetic resonance spectros-
copy) [45, 46].
MRI assessment of tissue iron
Relaxation theories
MRI evaluation of tissue iron overload is based on T2
relaxation enhancement induced from the interactions
between high-molecular-weight iron complexes such as
ferritin, haemosiderin and ferrioxamine with water mole-
cules [5, 47, 48]. Ferrioxamine is produced after cellular
uptake of DFO, and in extrahepatic tissues, where there is
no active excretion and it may remain for days [7].
Ferrioxamine-based agents have been used in the past as
contrast media because of their T2* effect [49]. “Inner
sphere” and “outer sphere” relaxation theories have been
proposed to explain the T2 relaxation enhancement induced
in siderotic tissues [50–55]. According to the inner sphere
theory, iron electron spins enhance the relaxation of protons
of water molecules buried in iron-containing proteins.
Enhanced relaxation of the bound water protons is then
transferred to the free water protons by water or proton
exchange [48, 56, 57]. According to the outer sphere
theory, magnetic field gradients induced at the periphery of
iron-containing proteins create loss of phase and relaxation
enhancement of free water protons diffusing in the
neighbourhood [53, 54].
MR methodologies
MR methods for assessing tissue iron can be separated into
two groups: signal intensity ratio (SIR) methods and
relaxometry methods. Various techniques have been de-
scribed, including: (a) methods measuring SIR based on
T2-weighted (spin-echo) or T2*-weighted (gradient-echo)
sequences [19, 23–26, 30, 58–62], (b) relaxometry methods
measuring absolute T2, (c) relaxometry methods measuring
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SIR methods
These have been used for the study not only of the liver but
also of other organs such as the spleen, pancreas, pituitary
gland, bone marrow and abdominal lymph nodes [19, 23,
25, 27, 30, 58–62]. For SIR assessment the signal intensity
of the target organ is divided by the signal intensity of a
reference tissue (e.g. fat, muscle) or noise. Signal intensity
measurements are performed in the same slice by using the
region-of-interest (ROI) method. For large organs such the
liver, spleen and pancreas more than one ROI is used,
positioned in areas lacking vascular structures and move-
ment artefacts [19, 23, 25, 27, 30, 58, 61, 62]. The mean
signal intensity from the different ROIs is then divided by
the signal intensity of the reference tissue. One ROI is used
for signal intensity measurement of the pituitary gland,
bone marrow, abdominal lymph nodes and the reference
tissue [58–60]. For SIR evaluation of the liver various
reference tissues have been used, of which paraspinal
muscle appears to be the best choice because it combines
good sensitivity with minimum intersite variability [19, 64].
A disadvantage of the SIR methods is that in most cases
they use only one echo time (TE) and thus lose their
detection sensitivity in tissues with heavy siderosis, where
transverse relaxation is much faster than the TE. This
occurs particularly in the liver at the upper range of LIC
values where signal intensities are widely dispersed [39].
Gandon et al. [19], by using an algorithm that combined
signal intensity ratios from multiple sequences with
different TEs, achieved extension of the detection range
up to about 21 mg Fe per gram dry liver tissue, with
sensitivity and specificity similar to those of biochemical
analysis.
T2 relaxometry methods
These assess T2 relaxation time or R2 (1/T2) by using the
Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequence,
which employs multiple (2–32) equidistant refocusing 180°
pulses, each followed by an echo [65, 66]. Most scanners,
by using a pixel-by-pixel, log-linear fitting model, auto-
matically derive the corresponding T2 maps. Signal
intensity measurements in the T2 maps correspond to the
mean T2 relaxation time of the included voxels [67]. To
avoid motion artefacts from respiration, studies of abdom-
inal organs should be performed with respiratory triggering.
To this end a pressure-sensitive pad is attached to the
abdomen and depending on the patient’s respiratory cycle a
delay time is chosen. Data acquisition takes place at the
end-expiration phase [39, 40]. During cardiac MRI, in
addition to respiratory triggering, cardiac triggering is
necessary. To obtain a minimum repetition time (TR) of
2,000 ms two to three R–R intervals should be allowed
between successive excitations [39, 40]. The mid-systole
phase and a cardiac trigger delay of around 250–300 ms are
usually chosen to image the myocardium with sufficient
thickness for the best signal intensity measurements [39,
40]. A pseudo four-chamber or short-axis view of the heart
is generally used. A T2 relaxometry method that received
FDA approval for clinical liver iron estimation has recently
been developed by St. Pierre et al. [44]. This method uses
multiple T2-weighted single spin-echo sequences with
different TEs acquired in half-Fourier mode to reduce
acquisition time. The calculated mean R2 values combined
with LIC values, obtained from liver biopsies, are used to
create calibration curves.
T2* relaxometry methods
These evaluate T2* or R2* (1/T2*) by using multiple
gradient-echo sequences with different TEs. These methods
have been developed to further accelerate acquisition, in
order to increase sensitivity and eliminate artefacts related
to respiration or cardiac motion. To obtain R2* (1/T2*)
values, the signal decay curve is usually fitted with an
exponential model: S=S0e
−TE/T2*, where S is the net image
signal intensity, TE is the echo time and S0 is a constant
[68]. T2* relaxometry methods have been used mainly for
myocardial iron assessment and cardiac gating is always
applied [35, 42, 68–71]. Breath-hold sequences have
greatly eliminated motion artefacts [35, 42, 68].
Hybrid relaxometry methods
Hybrid approaches have been applied in high fields and
measure both R2 and R2* to calculate the inhomogeneity
factor R2′=R2*−R2 [34, 72, 73]. These approaches assume
that R2′ is more specific to mechanisms of relaxation
related to iron than R2 [34, 73].
Comparison of the MRI methodologies
SIR versus relaxometry
SIR methods require shorter acquisition times but lack a
wide range of iron assessment [63]. Relaxometry meth-
ods, mainly the T2* method, by using multiple echoes
create in- and out-of-phase effects between water and
fat transverse magnetization (Fig. 1)[ 35]. Relaxometry
methods, although taking longer, are preferable because
they achieve a better sampling of the time domain in
which relaxation mechanisms take place and lead to more
precise results [63].
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There is no general consensus on which relaxometry
method (spin-echo or gradient-echo) or index (R2, R2*,
R2′) is best for tissue iron quantification. Theoretically, R2*
and R2′ are more sensitive than R2 to iron-induced field
inhomogeneities. Gradient-echo sequences evaluating R2*
are preferred for cardiac relaxometry, because of their short
acquisition time, but gradient-echo sequences are more
prone to artefacts and R2* is more dependent on factors
unrelated to iron, such as susceptibility artefacts from the
lungs and the blood oxygenation level-dependent (BOLD)
effect [35, 74]. According to the BOLD effect, the T2*
decreases as the concentration of intracapillary deoxyhaemo-
globin increases [74]. A pronounced BOLD effect may be
observed in early diastole and results in signal loss [75, 76].
Data collection during mid-systole helps to overcome BOLD
effect interference with accurate T2* measurements of the
myocardium. In liver and pituitary studies both T2 and T2*
have been assessed. T2* is more sensitive to low iron
content, but studies in the liver show that these methods
suffer from inaccuracies at high iron concentrations [77].
Furthermore, in high fields susceptibility artefacts from the
sphenoid sinus are more pronounced with gradient-echo
sequences and may lead to inaccurate measurements of
pituitary siderosis [43].
MRI studies of individual iron overloaded organs
The degree ofsiderosis, the crystalline structure offerritin, the
rateofironeliminationunder chelationtherapyandthe degree
of ferrioxamine formation are all organ-specific [7, 15, 18,
78]. All these parameters may be responsible for differences
in the T2 relaxation enhancement induced in the various
organs. Individual organs should be considered separately,
and the effect of age on iron overload should be taken into
account. Higher survival probabilities have been reported in
patients with thalassaemia born in the last 30 years [79].
Patient compliance with treatment regimens and effective
chelation therapy are thought to be the main factors
associated with improved survival [79]. The combination of
DFO, deferiprone and the new oral chelators is considered
very promising, but will require effective monitoring by non-
invasive methods [80]. An increasing number of studies have
evaluated iron in the various affected organs by MRI [19,
22–44]. Many of these studies have included paediatric
patients, but very few have investigated children younger
than 10 years and none has included children younger than
5y e a r s[ 17, 18, 28, 39, 43, 58, 60–62, 77, 81–84]. In
addition, very few studies have evaluated the effect of age on
individual organ siderosis and only one has evaluated and
compared MRI data from younger and older patients with
thalassaemia [28, 81, 82, 84]. Studies have tended to focus
on specific organs.
Liver
For the MRI evaluation of liver siderosis both SIR and
relaxometry techniques have been used (Fig. 2)[ 18, 23, 28,
32, 44, 68, 85]. R2 of the liver demonstrates a significant
positive correlation with serum ferritin and LIC determined
from liver biopsy material [18, 23, 32, 39, 40, 44, 68].
Comparative evaluation of hepatic R2 and R2* in iron-
overloaded patients demonstrates that both parameters
correlate closely with LIC [85]. The relationship of SIR
with LIC and serum ferritin varies among studies [18, 30,
58]. In most studies R2 and SIR show a better correlation
with LIC than with serum ferritin [18, 23, 28, 32, 44, 68,
85]. This can be explained in part because the HCV-
Fig. 1 A 15-year-old male with β-thalassaemia major. Axial scan
with a multiecho gradient-echo sequence (TR/TE 150/1.07, 2.14, 3.21,
4.28, 5.35, 6.42, 7.49, 8.56, 9.63, 10.7, 11.77, 12.84, 13.91, 14.98,
16.05, 17.12, 18.19, 19.26, 20.33, 21.4 ms; flip angle 35°). a Second
echo shows pixel annulation (arrows) due to out-of-phase phenomena,
at the interfaces of abdominal organs and muscles with fat. b Fourth
echo: no pixel annulation is observed because water and fat protons
are in phase (courtesy of Dr. M. Douskou)
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serum ferritin levels than those who were HCV-negative
[77, 86]. Liver R2 shows no association with the hepatic
inflammation histological activity index or the type of
hepatitis (chronic persistent or chronic active), but is
affected by hepatic fibrosis [18, 39, 77].
In iron overload states, over 70% of body iron is found in
the liver and LIC has been considered to be the best marker of
total body iron burden [7, 18, 19]. Based on the good
correlation between hepatic R2 or SIR and LIC a number of
recent studies have tested the relationship between siderosis
of the liver and other organs [28, 39, 40, 58–61, 87]. No
correlation has been found between liver and pituitary
siderosis [28, 58]. With regard to the heart, a correlation
with liver siderosis has been found only in cases of heavy
myocardial iron deposition [39, 40]. This lack of correlation
can probably be explained by differences in transferrin
receptor concentration, iron kinetics, the crystalline structure
of ferritin and the degree of organ inflammation or fibrosis
[7, 78, 88–92]. Furthermore, under chelation therapy with
DFO intracellular paramagnetic ferrioxamine is formed,
which exits slowly from cells unless there is an active
excretion pathway as is present in the hepatocytes [88].
Young patients with thalassaemia studied longitudinally
have shown absence of substantial improvement in the MR
parameters of liver siderosis under different chelation
therapy regimens [82]. This may be explained by the fact
that liver siderosis progresses very fast in thalassaemia
patients, and iron overload develops after only 2 years of
transfusion therapy [93]. Therapy with the most widely
used chelating agent is started at the age of about 3 years,
and until growth is completed DFO should not exceed a
dose of 40 mg/kg per day [7]. An early start to monitoring
the progress of tissue iron deposition with MRI might be
useful in deciding whether to begin chelation therapy at a
younger age and when to introduce new chelating agents.
Heart
Cardiac failure is the leading cause of death from iron
overload in patients with thalassaemia [94, 95]. Thalassaemia
patients on a regimen of regular blood transfusions who are
not receiving chelation therapy, develop heart enlargement
by the age of 10 years and heart failure by the age of
16 years [22]. Cardiomyopathy secondary to iron overload is
potentially reversible with vigorous chelation therapy [7].
Myocardial iron has been evaluated by MRI using SIR and
relaxometry techniques (Fig. 3)[ 22, 28, 39, 40, 68, 82, 96–
98]. In the prechelation era, post-mortem examination of
patients with thalassaemia showed a close correlation
between cardiac and hepatic iron concentrations. MRI
studies have demonstrated discordant results regarding the
relationship of myocardial iron with hepatic iron and serum
ferritin [28, 39, 40, 68, 97]. Differences in iron kinetics and
variations in chelation schemes may be responsible for the
lack of correlation of the MRI-determined myocardial iron
with that of the liver [88]. More active elimination of iron
from the hepatocytes than from the myocytes may play a role
in the absence of correlation in patients receiving chelation
therapy [28, 39, 68].
Fig. 3 A 16-year-old male with
β-thalassaemia major. a T2 map
of the short axis of the heart
shows low values of the left
ventricle (arrow) and the septum
(arrowhead). b R2* (=1/T2*)
map of the short axis of the
heart shows high signal of the
septum (asterisk). Note the re-
duction of motion artefacts and
better delineation of the heart
boundary in the R2* image
(courtesy of Dr. M. Douskou)
Fig. 2 A 17-year-old male with β-thalassaemia major. Axial scan,
fourth echo of a multiecho spin-echo sequence (TR/TE: 2000/20, 40,
60, 80, 100, 120, 140, 160 ms), shows low-signal intensity in the liver,
bone marrow of the spinal body and the pancreas suggesting iron
overload
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evaluated by MRI could predict which patient will develop
cardiac failure and arrhythmia. Thalassaemia patients with
significantly reduced left ventricular ejection fraction (LVEF)
have myocardial T2* values about 20 ms [22, 37, 38, 68],
although most patients with T2* values less than 20 ms have
normal LVEF [68]. Furthermore, the relationship between
myocardial R2 and LVEF is either non-existent or weak [22,
38–40]. Differences in cardiac functional indices among
patients with similar MRI measurement of iron might also be
explained by genetic factors that predispose to the more
rapid development of cardiac failure when a critical level of
myocardial siderosis is reached [99, 100].
Heterogeneous iron distribution in the myocardium has
been demonstrated in histological studies, and this would
suggestthenecessityforglobalMRIestimationofmyocardial
iron [42, 101]. Pepe et al. [42], using T2* multiecho cardiac
MRI, demonstrated that global T2* shows a close correlation
with midseptal T2*, suggesting that the latter may be used
for a quick assessment of myocardial siderosis.
MR studies have shown that cardiac siderosis increases
with age, but that siderosis progresses more slowly in the
heart than in the liver [28, 82]. Systematic MRI studies in
children are necessary in order to evaluate the age at the
start of cardiac iron overload.
Pituitary gland and brain
Increased iron deposition in the anterior pituitary gland is
the cause of hypogonadotropic hypogonadism and growth
hormone deficiency [102, 103]. Iron accumulates in all five
cell types of the adenohypophysis, but preferentially in the
gonadotropin-secreting cells [102, 103]. Gonadotropin cell
death due to iron toxicity is probably the cause of the
decreased pituitary gland height observed in thalassaemia
patients with hypogonadotropic hypogonadism (Fig. 4)
[104]. MRI has been used to evaluate pituitary siderosis
with SIR and relaxometry techniques [28, 43, 83, 105]. SIR
and R2 findings show significant correlation with serum
ferritin [83]. The very few studies evaluating simultaneous-
ly the pituitary and other solid organs have demonstrated no
correlation between their MRI parameters of siderosis [28,
43, 81]. Pituitary siderosis appears to increase with age, but
MR data are lacking for children under the age of 7 years
[28, 81][ 84].
The single study assessing iron in the brain of thalassae-
mia patients by MRI [106] showed significantly higher R2
values in the cortex, the putamen and the caudate nucleus in
patients than in controls. A lack of correlation between R2
and serum ferritin was found, possibly because serum
ferritin, which does not cross the blood–brain barrier, is not
a good marker of brain siderosis [106].
Pancreas
Iron overload leads to impairment of the endocrine and
exocrine functions of the pancreas [107, 108]. Pancreatic
siderosis has been evaluated in thalassaemia patients using
SIR techniques and relaxometry techniques [61, 84, 109].
Midiri et al. [109], using fat as the reference tissue, found a
significant negative correlation of SIR with serum ferritin
and trypsin. Papakonstantinou et al. [61], using muscle as
the reference tissue, found no relationship of the pancreatic
SIR with the hepatic SIR or serum ferritin. The findings of
Argyropoulou et al. [84], using T2 relaxometry techniques,
were similar. In addition, relaxometry techniques demon-
Fig. 4 The pituitary. a A 12-year-old male with β-thalassaemia major.
Midsagittal T1-weighted (TR/TE 500/20 ms) scan shows low-signal
intensity of the anterior pituitary lobe (arrow) and the bone marrow
(asterisks) suggesting iron overload. The pituitary gland is small
measuring 3.5 mm (normal for age 5.3±0.8 mm) [112]. This patient
developed hypogonadotropic hypogonadism. b An 11-year-old male
with β-thalassaemia major. Mid-sagittal T1-weighted (TR/TE 500/
20 ms) scan shows normal signal intensity of the anterior pituitary lobe
(arrow) along with normal pituitary gland height (6 mm). The bone
marrow (asterisk) shows low-signal intensity suggesting iron overload
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patients with thalassaemia is significantly lower in children
than in adults [84]. Fatty degeneration of the pancreas in
adult patients may explain these differences (Fig. 5).
Adrenals
Abnormalities in adrenal function have been reported in
patients with thalassaemia [103]. There is only one study
evaluating adrenals for iron overload with MRI (Fig. 5),
which showed a significant correlation between adrenal and
liver siderosis [87].
Spleen, lymph nodes and bone marrow
In spite of the fact that the spleen, lymph nodes and bone
marrow, which all contain reticuloendothelial cells, are
among the first organs to be affected by iron overload [1,
13], there have been very few studies evaluating their iron
overload in thalassaemia by MRI, and these used mainly SIR
techniques [59, 60, 62, 84]. SIR of the spleen shows a
significant correlation with serum ferritin but not with SIR of
the liver (Fig. 5)[ 62]. The absence of correlation between
liver and spleen siderosis could be explained by differences
in iron kinetics, by differences in the cluster size of iron
proteins, by haemochromatosis gene mutations in β-thalas-
saemia major carriers, and by the presence of extramedullary
haemopoietic tissue in the spleen [78, 110, 111]. Intra-
abdominal lymph nodes in β-thalassaemia have been related
to chronic hepatitis C [60]. Lymph node siderosis correlates
with liver, but not with spleen siderosis [60].
In the few studies that have been reported, SIR and
relaxometry methods have shown discordant results for MR
parameters of bone marrow siderosis and serum ferritin [59,
84]. Normal bone marrow signal associated with liver
siderosis has been reported in a few patients with
thalassaemia and this may be due to differences in genotype
or differences in chelation therapy regimens [59].
Conclusion
It is evident that MR relaxometry has the potential to
become the method of choice for non-invasive, safe and
accurate assessment of iron load. Further theoretical research,
along with studies monitoring wider age groups of patients
are needed before a generally accepted protocol can be
established. Until then, extreme caution is needed in its
clinicalapplication andinterpretation. Experimental artefacts,
non-optimized protocols, poor data analysis and unawareness
of the inherent limitations of current methodologies in
assessing a heavy body iron burden can result in misleading
diagnosis and inappropriate management of thalassaemia
patients with iron overload. Future experimental develop-
ments in relaxometry based on a better theoretical under-
standing of the contribution of the iron-containing proteins to
the MR signal are expected to further strengthen its clinical
role in the monitoring of patients with β-thalassaemia major.
Fig. 5 Siderosis of the spleen, pancreas and adrenals. a A 14-year-old
male with β-thalassaemia major. Axial scan, fourth echo of a
multiecho sequence (TR/TE 2,000/20, 40, 60, 80, 100, 120, 140,
160 ms) shows low-signal intensity of the liver, pancreas (arrow) and
spleen suggesting increased iron deposition. b A 27-year-old-male
with β-thalassaemia major and diabetes. Axial T2-W (TR/TE 1,800/
80 ms) scan shows low-signal intensity of the liver and adrenals
suggesting siderosis. High signal intensity of the pancreas (arrow)
suggests tissue damage and fatty degeneration
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